Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Bevacizumab + Interferon alfa (IFN-alfa) & Renal Cell Carcinoma (RCC), the US Food and Drug Administration (FDA) approved Bevacizumab + Interferon alfa (IFN-alfa) for the treatment of metastatic Renal Cell Carcinoma (RCC) in first‑line, cytokine‑treated patients, based on the BO17705 phase III trial showing a significant improvement in median progression‑free survival versus interferon alone. The FDA approval is specifically for metastatic Renal Cell Carcinoma (RCC) in adults, not restricted to a molecular subtype, and reflects the historical role of this regimen before VEGF‑tyrosine kinase inhibitors (…